| Name | Title | Contact Details |
|---|
The Permanente Medical Group was established in 1948 with seven original partners. Today, we are an integral part of Kaiser Permanente with the stability of more than 50 years serving the communities of Northern California. As the quality leader in
At T2 Biosystems, we are united in our mission: to improve patient outcomes, lower mortality rates and reduce the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. By leveraging the power of our innovative and proprietary T2 Magnetic Resonance (T2MR) platform, T2 Biosystems’ diagnostics are designed to provide faster, easier and more accurate results than traditional methodologies. T2 Biosystems is currently targeting a range of critically underserved healthcare conditions, focusing initially on those for which a rapid diagnosis will serve an important dual role – saving lives and reducing costs. Our T2Candida Panel tackles sepsis and is the first FDA-cleared diagnostic panel requiring no blood culture – delivering more accurate results in hours versus days. Other ongoing development efforts include bacterial and hemostasis panels, as well as a Lyme disease partnership with Canon Life Sciences. Over 100 studies published in peer-reviewed journals have featured T2MR technology in a breadth of applications, including the direct detection and measurement of targets in various sample types, such as whole blood, plasma, serum, saliva, sputum and urine. With limits of detection as low as 1 CFU/mL, we believe T2MR technology will drive the next generation of diagnostics.
Abiomed is a manufacturer of medical implant devices, including the AbioCor artificial heart and Impella. It is headquartered in Danvers, Massachusetts and has an additional office in Aachen, Germany. It has 500 employees.
Apherma Corp is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
PetVivo, Inc is an emerging biomedical device company focused on the licensing and commercialization of innovative medical devices for pets, or pet therapeutics. PetVivo believes that it can leverage the investments in the human biomaterials and medical device industries to commercialize therapeutics to pets in a capital and time efficient way. PetVivo`s strategy is to in-license proprietary products from human medical device companies specifically for use in pets. PetVivo, Inc, Gel-Del Technologies, Inc. and CosmetaLife a Corporation are all wholly-owned subsidiaries of PetVivo Holdings, Inc.